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Abstract – Epidemiological studies have demonstrated that most humans infected with Echinococcus spp. exhibit
resistance to disease. When infection leads to disease, the parasite is partially controlled by host immunity: in case
of immunocompetence, the normal alveolar echinococcosis (AE) or cystic echinococcosis (CE) situation, the meta-
cestode grows slowly, and first clinical signs appear years after infection; in case of impaired immunity (AIDS; other
immunodeficiencies), uncontrolled proliferation of the metacestode leads to rapidly progressing disease. Assessing
Echinococcus multilocularis viability in vivo following therapeutic interventions in AE patients may be of tremendous
benefit when compared with the invasive procedures used to perform biopsies. Current options are F18-fluorodeoxy-
glucose-positron emission tomography (FDG-PET), which visualizes periparasitic inflammation due to the metabolic
activity of the metacestode, and measurement of antibodies against recEm18, a viability-associated protein, that rap-
idly regresses upon metacestode inactivation. For Echinococcus granulosus, similar prognosis-associated follow-up
parameters are still lacking but a few candidates may be listed. Other possible markers include functional and diffu-
sion-weighted Magnetic Resonance Imaging (MRI), and measurement of products from the parasite (circulating anti-
gens or DNA), and from the host (inflammation markers, cytokines, or chemokines). Even though some of them have
been promising in pilot studies, none has been properly validated in an appropriate number of patients until now to be
recommended for further use in clinical settings. There is therefore still a need to develop reliable tools for improved
viability assessment to provide the sufficient information needed to reliably withdraw anti-parasite benzimidazole
chemotherapy, and a basis for the development of new alternative therapeutic tools.
Key words: Echinococcus multilocularis, Alveolar echinococcosis, Surgery, Medication, Follow-up, Em18, Em2,
FDG-PET.
Résumé – Les métacestodes d’échinocoques : à la recherche de marqueurs de viabilité. Les études
épidémiologiques suggèrent que la plupart des personnes infectées par les métacestodes d’échinocoques sont
résistantes au développement d’une maladie. Chez les malades, la croissance parasitaire est partiellement
contrôlée par l’immunité de l’hôte : s’ils sont immunocompétents, un développement lent du métacestode est à
l’origine de l’échinococcose alvéolaire (EA) ou kystique (EK) et les premiers signes apparaissent des années après
l’infection ; s’ils sont immunodéprimés (sida, autres situations d’immunosuppression), une prolifération incontrôlée
du métacestode s’accompagne d’une évolution rapide. Évaluer in vivo la viabilité larvaire après intervention
thérapeutique chez les patients atteints d’EA représenterait un avantage considérable sur les méthodes invasives
(biopsies des lésions). Les options non-invasives sont la tomographie par émission de positons au F-18
fluorodeoxyglucose (FDG-TEP), qui visualise l’inflammation péri-parasitaire associée à l’activité métabolique du
métacestode, et la détermination des taux d’anticorps dirigés contre Em18, une protéine associée à la viabilité
parasitaire ; leur sécrétion régresse rapidement lors de l’inactivation du métacestode. Pour E. granulosus, on
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manque de paramètres similaires ; on peut cependant lister quelques candidats. D’autres marqueurs sont à l’étude : ils
incluent l’imagerie en résonance magnétique fonctionnelle ou pondérée en diffusion, et le dosage de substances
parasitaire (antigènes circulants, ADN), ou sécrétées par l’hôte (marqueurs d’inflammation, cytokines,
chimiokines). Bien que certains aient paru prometteurs dans des études pilotes, aucun n’a été validé sur un
nombre suffisant de patients pour pouvoir être recommandé en suivi clinique en routine. Il reste indispensable de
développer des outils fiables susceptibles d’apporter l’information nécessaire pour arrêter la chimiothérapie par
benzimidazoles, ou d’être utilisés pour le développement de nouveaux outils thérapeutiques.
1. Introduction
The genus Echinococcus includes more than seven differ-
ent species plus multiple genotypes [38]. Among them,
Echinococcus multilocularis (the small fox tapeworm) is the
most pathogenic, and causes alveolar echinococcosis (AE).
The distribution of E. multilocularis is largely restricted to
the Northern hemisphere and highest prevalence occurs in
Central Asia, Russia, Northwestern China, and parts of Europe
and Japan. Across the European endemic countries such as
France, Germany, Austria and Switzerland, where AE cases
were notified for many decades already in the past century,
AE is basically still considered a rare disease with average inci-
dences of 0.03–0.30/100,000 inhabitants/year [51]. These
figures, however, do not reflect the situation of the actual pop-
ulation at risk; far higher incidences, from 4.7 to 8.1 cases per
100,000 inhabitants/year, are observed in areas where humans
are directly exposed to E. multilocularis infection in the same
countries [39, 47, 49]. In Europe and Canada, emergence and geo-
graphical increase in endemicity have been reported [7, 9, 16].
Echinococcus granulosus sensu lato (the small dog tape-
worm) represents the most common species and occurs in both
hemispheres; predominantly affected regions include the Med-
iterranean area, Eastern Europe, parts of South America, parts
of Africa, and Central Asia/Western China.
Both parasites cause life-threatening diseases of serious
public health and economic concern worldwide [58]. Mainly
cystic echinococcosis (CE), but to some extent also alveolar
echinococcosis (AE), are diseases of predominantly resource-
poor low-income communities, but they also occur in
middle-income or wealthy countries. For both CE and AE,
the number of patients is most likely underestimated or under-
reported [27]. Globally, AE causes an annual loss of approxi-
mately 660,000 disability-adjusted life years [57]. Necessary
long-term chemotherapy of echinococcosis using benzimidaz-
oles, i.e. albendazole and mebendazole, which are the only
available drugs with some efficacy, and the difficulty of making
the decision for its safe withdrawal on clinical grounds are
among the main factors for the economic cost of the disease,
and the chronic impairment of patients’ quality of life [57, 59].
Epidemiologically, humans represent an aberrant ‘‘interme-
diate host’’ for these parasites. Infection is acquired through
the accidental ingestion of eggs, released with the feces of
infected carnivores, the ‘‘definitive hosts’’. Eggs contain the
infectious larval oncosphere, which actively penetrates the
intestinal lining, and migrates via blood and lymphatic vessels
to specific target sites. Most commonly affected organs in
humans are the liver for E. multilocularis (AE), and the liver,
lung, and many other sites for E. granulosus (CE). There, the
oncosphere develops into the metacestode, with serious
consequences for those individuals susceptible to its growth [28].
Within such a metacestode, protoscoleces might develop,
which represent the infectious unit for definitive hosts.
Development of protoscoleces depends on the host species
and other, most likely immunological, factors provided by or
lacking in their host. If such a fertile metacestode is ingested
by a suitable definitive host, the life cycle is concluded, in that
the protoscolex matures into an adult-stage tapeworm in the
small intestine of this definitive host, and adult parasites start
to produce parasite eggs 4 weeks p.i. for E. multilocularis
and 5–6 weeks p.i. for E. granulosus.
Biologically, metacestodes are fluid-filled vesicles that are
separated into (i) an inner ‘‘germinal layer’’representing the living
and metabolically active parasite tissue, and (ii) an outer, acellular
compartment known as the ‘‘laminated layer’’, mediating the
direct physical contact with cells of the host’s inflammatory
response, i.e. cells of the immune system and other cells such
as parenchymal cells and fibroblasts. The distal part of the germi-
nal layer, the tegument, is directly associated with the inner
surface of the laminated layer. The tegument is characterized
by microvilli-like extensions termed microtriches, which pro-
trude well into the matrix of the laminated layer, and increase
the resorbing surface of the parasite. In addition, the germinal
layer contains highly differentiated cell types including connec-
tive tissue, muscle cells, and glycogen storage cells, as well as
many undifferentiated cells, e.g. ‘‘stem’’ cells. The outer lami-
nated layer is a carbohydrate-rich structure which is synthesized
by the parasite and secreted into its peripheral entities, and which,
in terms of thickness, is much more prominent in E. granulosus
metacestodes where it is surrounded by a very prominent host-
derived fibrous adventitial layer. In contrast to E. granulosus,
E. multilocularis metacestodes are not surrounded by such an
adventitial layer. Instead, the parasite larva represents a multi-
vesicular organism that reproduces asexually, by exogenous for-
mation of daughter vesicles. Periparasitic cells of the immune
response exhibit a ‘‘granulomatous’’ arrangement and are directly
in contact with the organ parenchyma on the one hand, and with
the laminated layer of the budding daughter vesicles on the other.
This process is often referred to as ‘‘progressive tumor-like
growth’’, and leads to the formation of a large and heterogeneous
parasitic mass consisting of mostly peripheral, actively proliferat-
ing, sites, and in many cases, centrally located necrotic tissue.
The release of metacestode structures such as microvesicles
(for E. multilocularis) or protoscoleces (for E. granulosus) into
the blood or lymphatic vessels may lead to metastases
formation in other organs.
Spontaneous cure of AE or CE leading to calcified lesions
is possible and even frequent, but it is not known how this
event is initiated and terminated with such a favorable and for-
tunate prognosis. Mass screenings in endemic areas have
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revealed that the number of established AE infections in
humans is far lower than the number of seropositive humans
that had been exposed to the eggs of the parasite but remained
clinically healthy, and following estimations, only 1–10% of
individuals infected with E. multilocularis (as determined upon
species-specific seropositivity) are assumed to subsequently
develop disease (i.e. AE). Similarly, spontaneous abortion of
already developed parasite cysts in E. granulosus infection,
without any treatment, has been repeatedly shown by the teams
that performed appropriate follow-up after mass screening in
South America and China [15, 62].
This indicates that in the largest percentage of individuals,
innate or acquired immunity can contribute to the control of
the parasite for both species, either early or later after infection.
Conversely, impairment of cellular immunity such as observed
in advanced AIDS or other immunological disorders is associ-
ated with a rapid and unlimited growth and dissemination of
the parasite in AE [9, 50]. CD4+ T-cell recovery in AIDS
patients by means of appropriate therapy, however, reinstates
control over progression of AE treated with benzimidazoles
[69]. All these observations consequently open the way for
development of appropriate immunotherapeutic tools, includ-
ing vaccines, and for closer monitoring of patients in order
to evaluate parasite viability, and thus to adjust and optimize
anti-parasite therapies [66].
2. Viability: increase, decrease, dying-out
In infected humans, the E. multilocularis metacestode
(larva) develops primarily in the liver, and a granulomatous
host reaction surrounds the metacestode, including a vigorous
synthesis of fibrous and healing tissue. In contrast to infections
in susceptible rodent hosts, lesions from infected human
patients rarely exhibit brood capsule and protoscolex formation
within vesicles. The kind of immune response developed by
the host accounts for the subsequent dichotomy concerning
parasite development [54]: (i) resistance as shown by the
presence of ‘‘dying-out’’ or ‘‘aborted’’ metacestodes (Figure 1);
(ii) controlled susceptibility as shown by a slowly growing
metacestode tissue – this group refers to normal AE patients
who first experience clinical signs and symptoms 5–15 years
after infection, and (iii) uncontrolled hyperproliferation of
the metacestode due to an impaired immune response because
of AIDS or other immunodeficiencies, e.g. following ortho-
topic liver transplantation, and in patients with drug-induced
acquired immunodeficiency after other types of allogeneic
transplantation or chemotherapy/biotherapy for malignant or
chronic inflammatory diseases [9]. The host immune mecha-
nisms modulating the course of infection include primarily
T-cell interactions. Thus, the periparasitic granuloma contains
a large number of CD4+ T cells in patients with abortive or
dead lesions, whereas in patients with active metacestodes
the number of CD8+ T cells is increased [61]. The parasitic
metacestode itself seems to initiate, predominantly by means
of bioactive metabolites, immunosuppressive and/or immuno-
regulatory processes that are assumed to correlate to parasite
survival and proliferation dynamics [60]. Cytokine mRNA lev-
els in peripheral blood mononuclear cells (PBMCs) during AE
show initially elevated transcription levels of pro-inflammatory
cytokines, e.g. IL-1b, IL-6 and tumor necrosis factor
alpha (TNF-a), as well as Th1 cytokines, i.e. IL-12 and
Interferon-c, which are gradually re-oriented toward Th2,
including elevated IL-13, IL-4, IL-5, and IL-10 [19, 61]. Trans-
forming Growth Factor (TGF)-b transcripts are prominent in
the periparasitic infiltrate which surrounds the lesions, both
in the liver of patients with AE [65, 68] and in the liver of
experimental mice [63]; in such mice, all members of the
TGF-beta/Smad pathway are markedly expressed, and there
is subtle interplay with members of the IL-17 family [63].
TGFb-driven regulatory T cells were shown to play a crucial
role in the parasite-modulated progressive course of AE [37].
However, among the immune cells which surround the meta-
cestode, both Th1 and Th2 cytokine- and chemokine-secreting
cells are numerous and IL-4 as well as INF-c expression are
increased from the very early stage of infection [63], which
suggests that a secondary re-orientation of the immune
response toward protection or tolerance may be crucial for
the outcome of the infection. In the experimental murine
model, such re-orientation toward resistance has been attrib-
uted to IL-12 [13], TNF-a [13, 25], and IFN-a [20]. In humans,
only IFN-a administration was shown to lead toward some
regression of AE lesions [22].
The response characteristics of AE-resistant persons have
not been fully elucidated so far. One study suggested that, in
patients with aborted lesions, secretion of IL-10 and Th-2 cyto-
kines by PBMCs of AE patients was lower than in patients with
a progressing disease [18]; another study suggested that pro-
gression of lesions, and the associated cytokine profile,
could be related to genetic determinants of the immune
response, such as the presence of the HLA-B8, DR3, DQ2
haplotype [17]. Other cytokines and chemokines secreted by
the periparasitic immune cells also seem different in patients
with regression versus progression of the disease [25, 29].
From the clinical point of view, in vivo assessment of
metacestode activity status is essential with a view to designing
an optimal individual treatment strategy for a given AE
patient [6]. In addition, non-invasive methods would be pre-
ferred by the majority of clinicians who express remarkably
strong demand for improved tools to assess in vivo the viability
or non-viability status of treated hepatic and extra-hepatic echi-
nococcosis lesions.
3. Imaging follow-up of AE and CE patients
for parasite viability assessment
Progression of lesions, at least in immunocompetent
patients, is extremely slow in AE, and prolonged follow-up
is necessary before ruling on regression or progression.
Improvement in the determination of lesion size has been pro-
posed to improve the detection of changes in AE lesions [3].
However, whatever the imaging technique used, ultrasonogra-
phy (US) [15], Magnetic Resonance Imaging (MRI), or Com-
puted Tomography (CT), progression is better assessed than
regression, and decrease in lesion size after drainage of a cen-
tral cavity cannot be interpreted as regression; it simply corre-
sponds to the shrinking of the central part of the lesion,
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irrespective of the viability of the peripheral metacestode
vesicles [44]. Calcification of lesions, and its increase which
indicates efficient protective immune response with subsequent
degeneration of the parasite, cannot be used as a reliable mar-
ker of parasite death in the whole lesion [6]. Preliminary results
from the comparison between MR images and [18F]-fluorode-
oxyglucose (FDG) Positron Emission Tomography (PET) sug-
gest that identification of microvesicles in AE lesions by MRI
strongly suggests ‘‘metabolically active’’, hence viable, meta-
cestode [2]; however, before being reliably used as a marker,
studies on a larger cohort of patients with and without anti-
parasite treatment withdrawal will be necessary.
FDG is currently the only validated tracer of AE lesions; it
was proposed 15 years ago to assess progression of lesions, if
positive, and as a marker of parasite abortion and thus indica-
tion of benzimidazole withdrawal, if negative [43, 45]. This
approach has proven effective in several patients, but drug
withdrawal was followed by recurrence in some of them
[45, 55]. Improvement in the PET imaging procedure, better
adapted to the specific situation of AE, has been proposed: it
is now accepted that PET may only be considered negative if
images acquired 3 h (and not only 1 h) after FDG injection
are negative [8]. In fact, FDG-PET images do not
directly reflect parasite viability but rather periparasitic host
Figure 1. In addition to conventional AE found in human patients, so-called abortive (resistant, R) cases, where the parasite metacestode has
spontaneously died out, are more and more frequently found. R1: by imaging techniques (e.g. CT), an abortive metacestode lesion (arrow)
appears as a small, fully calcified structure. A surgically resected liver lobe containing such a lesion (arrows) is shown in R2 and following
opening in R3. Histologically, an abortive lesion appears as an acellular structure, centrally composed of a collagenous and fibrous mass
(cfm) void of any metacestode structures such as the germinal or laminated layers (R4, HE-stain; ·400); this mass is surrounded by a layer of
fibrous connective tissue that still contains some laminated layer fibers and some parasite DNA (PCR-positivity of the material), but no
remaining live parasite cells; there is still some inflammatory reaction around this died-out lesion, putatively responsible for the maintenance
of a positive humoral immune response such as anti-Em2-seropositivity. In contrast, the classical viable AE metacestode lesion (V1, HE-
stain; ·200) is composed of fluid-filled microvesicles that may rarely contain protoscolices (p); the actual living metacestode structure is the
very thin germinal layer (arrow), which is closely adjacent to the PAS-positive outer laminated layer (V2, PAS-stain; ·200), indicated by the
arrow. Before dying-out, the metacestode undergoes a transitional stage where it becomes more tightly encapsulated within a fibrous-
collagenous mass, and where the germinal layers start to disappear, while the PAS-positive laminated layer still remains prominently present
as vesiculated structures (T1, PAS-stain, ·100).
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inflammatory processes. This is supported by the location of
FDG uptake by the lesion, only in those areas where the peri-
parasitic infiltrate by immune cells is dense, and by an in vitro
uptake of FDG by leucocytes far higher than the uptake by
E. multilocularis cells or vesicles [42]. The correlation we
found between images of microvesicles on MRI and positive
FDG-PET is likely explained by more numerous and
metabolically active immune cells in those areas of the lesions
where active vesicles with clearly differentiated solid and
liquid components are present [2].
The ideal PET tracer should be able to assess the course of
AE upon direct uptake by the metacestode through its meta-
bolic activity [41] or by binding to parasite molecules only
present when the metacestode is viable. Respective candidates
may be available among PET tracers already used for diagnosis
or follow-up of other diseases such as [18F]-fluorotyrosine
(FET), [18F]-fluorothymidine (FLT), [18F]-fluoromethylcho-
line (FMC), and sodium [18F]-fluorine (NaF) [41]. Preliminary
in vitro results show that E. multilocularis germinal cells have
a far higher uptake of Fluoro-L-Thymidine (FLT) than of FDG
[42]. Such preclinical studies will require appropriate animal
models for micro-PET/CT or MR imaging: mice and rats
appear to be the most suitable animal species so far for suscep-
tibility studies.
Therapeutically, one might consider using a similar tracer
or designing ligand techniques making use of the specificity
of anti-Echinococcus antibodies and of the cytotoxic properties
of beta-radiation from radioisotopes, e.g. Lutetium 177 or
Yttrium 90.
Ultrasonography (US) and CT have been assessed for
evaluating efficacy of AE treatment [35]. Especially CT was
suitable to classify the pattern of hepatic lesions into three
types: solid form, pseudocystic form, and ‘‘geographic map’’
(mixed) form, which correlated well with other clinical find-
ings that may either indicate cure or still progredient course
of disease. Earlier reports [see 59] had already suggested that
for an accurate disease evaluation, aiming to guide the surgical
strategy, beside CT, Magnetic Resonance (MR) imaging,
including cholangio-MR imaging can yield useful additional
information.
The international classification of CE cysts has been
designed with the purpose of differentiating between ‘‘active/
progressing/viable cysts’’ and ‘‘inactive/degenerating/dead’’
cysts (ref WHO classification). CE1 and CE2 cysts are highly
likely viable, and CE4 and CE5 cysts likely degenerating; CE3
cysts being considered to be ‘‘transitional cysts’’, since they
may either degenerate and move to CE4 or CE5, or give rise
to daughter vesicles, as shown in CE2 [54]. Follow-up of
patients, either in hospital settings or after mass screening,
has however shown that CE1 cysts could spontaneously degen-
erate, and that CE4 and even CE5 cysts could sometimes show
increase in size and progression [45, 53]. None of the available
imaging procedures are currently able to accurately assess
E. granulosus viability and/or predict cyst progression/abor-
tion. Metabolic viability assessment of CE using high-field
1H-MRS of cyst content has been proposed to provide further
information on cyst viability [24], but this approach has not yet
received further validation. FDG-PET is negative in most cases
of CE and is of no use for the assessment of parasite viability
or disease progression. Nevertheless, through ultrasound,
substantial progress has been made in recent years in under-
standing the natural and treatment-driven involution of CE
cysts [54]. In addition, MRI reproduces US-defined features
of CE better than CT. If US cannot be performed due to cyst
location or patient-specific reasons, MRI with heavily
T2-weighted series is preferable to CT [54]. As treatment deci-
sions are driven by imaging findings, it is nevertheless impor-
tant to know how US-based classification of CE cysts translates
into MR- and CT-imaging for cases where MRI and CT substi-
tute for US. This holds especially true for cysts that are not
accessible to US. Larrieu et al. [30] have successfully used
ultrasonography to monitor treatment of CE with albendazole.
Ultrasonography was also used to understand how cyst struc-
tures alter with time to evaluate the effectiveness of different
treatment regimes and to understand natural degeneration of
cysts that can occur. Such studies have been undertaken in
various geographically and ethnically diverse communities
[11, 34, 47]. Ultrasonography, for the same purposes, also
proved useful for pediatric CE cases [17].
4. Biological follow-up for CE patients
Any kind of treatment for any case of CE, including sur-
gery, implies long-term follow-up of the patient, which is
needed to detect relapses. Based on the standardized US-based
monitoring used for the follow-up of CE patients, for some
specific cases, cyst puncture with direct assessment of parasite
viability (assessment of the presence of protoscoleces) may be
proposed. However, this type of invasive technique cannot be
recommended and hardly applies to most of the patients treated
by benzimidazoles for multiple cysts and/or cysts in locations
inaccessible to safe puncture.
In parallel, follow-up laboratory analyses to monitor drug
tolerance include liver enzymes (aminotransferases) and leuko-
cyte count; they provide little information on the sensitivity of
the parasite to treatment. The search for immunological param-
eters useful in the staging and prognosis of CE in treated
patients has yielded scarce practical tools so far. Presence of
circulating antibodies against parasite antigens is observed in
only 50–80% of patients, depending on the stage and location
of the cyst(s) [10, 14, 21], and most of the target antigens for
the antibodies that are the most efficient for diagnosis remain
present in cysts which have lost any viability, which prevents
the use of the corresponding antibodies for follow-up. In those
patients with positive serology at diagnosis, follow-up of anti-
body isotypes and immune complexes was already proposed a
long time ago to discriminate between responders and non-
responders to albendazole treatment. However, since then,
the usefulness of immune-complexes monitoring has not been
validated by other teams. Siracusano et al. [53] reported on
HSP20 as a potential marker of active CE. Their immunoblot
analysis revealed anti-HSP20 antibodies in a statistically
significant higher percentage of sera from patients with active
disease than in sera from patients with inactive disease. Anti-
HSP20 antibody levels significantly decreased over the course
of chemotherapy in sera from patients with cured disease,
when compared to sera from patients with progressive
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disease. Hernandez-Gonzalez et al. [23] showed that the
B2t-IgG-ELISA is of a better prognostic value for the fol-
low-up of surgically treated CE patients than other conven-
tional Echinococcus-ELISAs. Similar findings were reported
by Ben Nouir et al. [4], who documented a relatively rapid
decrease of anti-recP29 antibody levels in young CE patients
who had been successfully treated by surgery, while relapsing
CE patients continued or newly developed an anti-recP29 level
following treatment. Post-treatment positive specific IgG anti-
body seroconversion against recAgB in initially seronegative
CE1 patients was considered a good indication for positive
therapeutic efficacy of albendazole, as reported by Li et al.
[33]. Prospectively, promising new tools helpful for post-
treatment monitoring of CE patients by laboratory methods
may rather be developed in the domain of circulating antigen
detection [14], the disappearance/absence of which should
more rapidly reflect parasite inactivation than conventional
antibody detection [67]. A recent study showed that circulating
antigen B was present in the sera of 90% of antibody-negative
CE patients and suggested that its detection could markedly
improve CE diagnosis [32]; however, circulating antigens
and/or their levels have not been fully studied as viability
markers as yet [48].
A correlation between CE stage and selected Th1 versus
Th2 cytokine profiles was investigated by Piccoli et al. [40].
With the exception of the association of IL-4 and IL-13 with
the cyst stage, all other cytokines did not associate with cyst
stages. A more optimistic presentation of using cytokines to
assess efficacy of CE treatment was reviewed by Siracusano
et al. [53]. Their conclusion was that patients who responded
to chemotherapy produced high amounts of IFN-c, whereas
patients who did not respond produced IL-4 and IL-10.
At the mRNA level, patients in whom therapy failed, weakly
expressed IL-4 mRNA before therapy, and strongly thereafter;
patients who responded to therapy expressed higher IFN-c and
TNF-a mRNA values than patients who did not [46].
5. Biological follow-up for AE patients
In AE patients, testing of parasite viability can be per-
formed with RT-PCR of biopsies and fine-needle aspirates on
various constitutively expressed gene targets (e.g. 14-3-3)
[12], within the limits of the sensitivity of this method [26,
36, 65]. However, due to these limits, this invasive technique
cannot yet be recommended for routine follow-up.
In AE patients, follow-up after surgery and chemotherapy
is probably best life-long. Cases of recurrence have been
observed almost 20 years after surgery [1]. Better than for
CE, in AE some specific serologic tests are valuable to assess
the efficacy of treatment in combination with imaging during
follow-up of patients [26, 52]. Disappearance of IgE and
IgG4 isotypes of anti-Echinococcus specific antibodies was
reported to be associated with good prognosis and absence
of recurrence after surgery and chemotherapy in AE patients;
conversely, reappearance of specific IgG4 antibodies was a
strong indication of recurrence [67]. This was confirmed in
another series of patients, which also showed that in AE
patients with progressive disease, IgG4 distinctively recognized
low molecular weight EmAg of Mr 26 kDa, 18 kDa, 16 kDa,
and 12 kDa [reviewed in 52]. In a more recent study,
E. multilocularis metacestode-specific IgG1, IgG3, and IgE
responses progressively diminished with regression from active
to stable and cured AE. IgG2 and IgG4 reactivity remained
similarly high in stable and progressive cases, and lessened
only with cured AE [25]. However, such isotype determina-
tions do not seem to have entered routine follow-up of AE
patients, and should perhaps be evaluated further in a larger
series of patients.
After successful surgery and/or chemotherapy leading to
inactivation of the parasite, anti-Em18 (and to a certain extent
anti-Em2+) antibody decline is rapid, and seroconversion
to undetectable levels correlates well with curative resection
[1, 5, 56]. It is likely that this type of antibody detection for
follow-up will rely on thresholds different from those estab-
lished for diagnosis [5]; definition of ‘‘follow-up thresholds’’
as well as the value of combined antibody and FDG-PET
images need to be assessed in a significant number of patients
with prospective follow-up. As suggested above for CE, for
post-treatment monitoring of AE patients, the detection of
circulating antigens may more directly reflect parasite metabo-
lism and thus viability, or, in case of absence, parasite inactiva-
tion. Presence and, if positive, concentrations of circulating
E. multilocularis DNA could also be studied in patients with
active lesions before and after various types of treatment.
Cytokine and chemokine levels, alone or combined with
other circulating markers, might be used as follow-up markers:
in a recent study of German patients with AE, the spontaneous
cellular release of pro-inflammatory IL-31 and IL-33 was
clearly depressed in all AE patients, while regulatory IL-27,
anti-inflammatory SDF-1/CXCL12, and eosinophil granulo-
cyte attracting Eotaxin-1, Eotaxin-2, and Eotaxin-3 (CCL11,
CCL24, CCL26) were enhanced with disease progression [25].
Kocherscheidt et al. [29] compared characteristic chemo-
kine profiles and changes in their production in AE patients
versus infection-free controls in antigen-stimulated PBMCs.
The production of CC and CXC chemokines that associate
with inflammation (MIP-1 alpha/CCL3, MIP-1 beta/CCL4,
RANTES/CCL5, and GRO-alpha/CXCL1) was constitutively
larger in AE patients than in controls; and the elevated chemo-
kine releases were equal in patients with progressive, stable, or
cured AE. A disparate cellular responsiveness was observed in
AE patients upon chemokine cluster analyses: cluster 1 and
cluster 2 chemokines were clearly diminished, while cluster
3 chemokines augmented in AE patients. Lechner et al. [31]
studied the pro-inflammatory IL-17 cytokine family members
and their common receptors. The study disclosed divergent cel-
lular production profiles and plasma levels in AE patient
groups and controls; Th17-type IL-17A levels were similar
in patients with progressive, stable, and cured E. multilocularis
metacestode lesions, IL-17B increased in AE patients, while
the Th17-type IL-17F production was highest in controls and
depressed in all AE patient groups similarly [31].
The regulatory T-cell effector Fibrinogen-Like Protein
2 (FGL2) is a recent additional candidate to discriminate
between patients with active and inactive lesions: its role
as an important mediator of the tolerance status in E. multiloc-
ularis infection has received experimental confirmation [64];
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preliminary results have shown that its soluble form is
significantly increased in the serum of patients with AE com-
pared to healthy subjects; however, its association with disease
course and prognosis is still under investigation (Junhua Wang,
personal communication).
6. Conclusions
For both CE and AE, clinicians have to assess efficacy and
efficiency of treatment protocols, and to decide whether treat-
ment has reached an endpoint where the parasite has lost all
potential for further proliferation and thus where the disease
is definitively extinct. The search for improved possibilities
to determine metacestode viability in vivo is ongoing. There
is an urgent need for well-validated non-invasive markers: they
may consist of imaging features or biological markers or both.
The significant advances in our knowledge of Echinococcus
biology at the molecular level and on the host’s immune
response have now facilitated the search for novel and poten-
tially suitable follow-up tools that will provide the sufficient
clinical information needed to reliably stop anti-parasite treat-
ment. Validation of new tools, however, relies on the capacity
of clinical research teams to set up patient cohorts that will
make statistical comparisons relevant and enable recommenda-
tions based on solid evidence. To reach this goal, it is thus
important to increase public awareness of the impact of AE
and CE on society, in order to generate resources to carry
out such research and studies.
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